{
    "Variants Include": [
        {
            "Gene": "LRRK2",
            "variants": [
                {
                    "HGVS": "NM_198578.3:c.6055G>A",
                    "cDNA Change": {
                        "transcript": "NM_198578.3",
                        "ref": "G",
                        "alt": "A",
                        "position": "6055"
                    },
                    "Protein Change": {
                        "ref": "G",
                        "alt": "S",
                        "position": "2019"
                    },
                    "Description in input context": "G2019S"
                },
                {
                    "HGVS": "NM_198578.3:c.6059T>C",
                    "cDNA Change": {
                        "transcript": "NM_198578.4",
                        "ref": "T",
                        "alt": "C",
                        "position": "6059"
                    },
                    "Protein Change": {
                        "ref": "I",
                        "alt": "T",
                        "position": "2020"
                    },
                    "Description in input context": "I2020T"
                }
            ]
        }
    ],
    "Described Disease": {
        "Described Disease": "Parkinson’s disease",
        "MONDO": "MONDO:0005586"
    },
    "Experiment Method": [
        {
            "Assay Method": "TR-FRET competitive binding assay",
            "Material used": {
                "Material Source": "Protein",
                "Material Name": "LRRK2 (amino acids 970–2527) wild-type, G2019S, and I2020T",
                "Description": "N-terminal GST-tagged LRRK2 (amino acids 970–2527) wild-type, G2019S, and I2020T were from Invitrogen Corporation." 
            },
            "Readout type": "Quantitative",
            "Readout description": [
                {
                    "Variant": "NM_198578.3:c.6055G>A",
                    "Conclusion": "Abnormal",
                    "Molecular Effect": "N.D.",
                    "Result Description": "G2019S has approximately 2-fold lower ATP affinity than wild-type LRRK2.The ATP affinity of G2019S is about 2-fold lower than wild-type LRRK2." 
                },
                {
                    "Variant": "NM_198578.3:c.6059T>C",
                    "Conclusion": "Abnormal",
                    "Molecular Effect": "N.D.",
                    "Result Description": "I2020T has approximately 6-fold higher ATP affinity than wild-type LRRK2.I2020T has an approximately 9-fold higher affinity for ATP than wild-type LRRK2." 
                }
            ],
            "Biological replicates": {
                "Biological replicates": "N.D.",
                "Description": "N.D."
            },
            "Technical replicates": {
                "Technical replicates": "Yes",
                "Description": "All assays were performed using either three or four replicates for each data point represented." 
            },
            "Basic positive control": {
                "Basic positive control": "Yes",
                "Description": "Binding assays were performed with various concentrations of each inhibitor as the competitor. The affinities were 39 +/- 1, 4.5 +/- 1 and 75 +/- 1 µM for wild-type, I2020T, and G2019S, respectively." 
            },
            "Basic negative control": {
                "Basic negative control": "N.D.",
                "Description": "N.D."
            },
            "Validation controls P/LP": {
                "Validation controls P/LP": "N.D.",
                "Counts": "N.D."
            },
            "Validation controls B/LB": {
                "Validation controls B/LB": "N.D.",
                "Counts": "N.D."
            },
            "Statistical analysis method": {
                "Statistical analysis method": "N.D."
            },
            "Threshold for normal readout": {
                "Threshold for normal readout": "N.D.",
                "Source": "N.D."
            },
            "Threshold for abnormal readout": {
                "Threshold for abnormal readout": "N.D.",
                "Source": "N.D."
            },
            "Approved assay": {
                "Approved assay": "Yes"
            }
        },
        {
            "Assay Method": "Radiometric kinase activity assays",
            "Material used": {
                "Material Source": "Protein",
                "Material Name": "LRRK2 (amino acids 970–2527) wild-type, G2019S, and I2020T",
                "Description": "N-terminal GST-tagged LRRK2 (amino acids 970–2527) wild-type, G2019S, and I2020T were from Invitrogen Corporation." 
            },
            "Readout type": "Quantitative",
            "Readout description": [
                {
                    "Variant": "NM_198578.3:c.6055G>A",
                    "Conclusion": "Abnormal",
                    "Molecular Effect": "N.D.",
                    "Result Description": "The ATP Km,app value for G2019S (169 µM) was approximately 3-fold higher than wild-type LRRK2 (51 µM), whereas the specific activity for G2019S was approximately 3-fold higher." 
                },
                {
                    "Variant": "NM_198578.3:c.6059T>C",
                    "Conclusion": "Abnormal",
                    "Molecular Effect": "N.D.",
                    "Result Description": "I2020T showed both lower Vmax and a much lower ATP Km,app than wild-type. The ATP Km for I2020T was found to be 7.5 ± 0.4 µM, which is 7-fold lower than that for wild-type LRRK2. The Vmax for I2020T was found to be 44 nmol/(min mg), which is 3-fold lower than that for wild-type LRRK2." 
                }
            ],
            "Biological replicates": {
                "Biological replicates": "N.D.",
                "Description": "N.D."
            },
            "Technical replicates": {
                "Technical replicates": "Yes",
                "Description": "Kinase reactions were performed in duplicate at room temperature in Kinase Buffer S (50 mM Tris-HCl, pH 8.5, 10 mM MgCl2, 1 mM EGTA, 0.01% Brij-35) with 2 mM DTT, 400 µM LRRKtide, variable amounts of cold ATP, and 0.5 µCi γ32P ATP at a final volume of 30 µL." 
            },
            "Basic positive control": {
                "Basic positive control": "Yes",
                "Description": "Kinase concentrations were 10 nM for wild-type and I2020T and 4.9 nM for G2019S." 
            },
            "Basic negative control": {
                "Basic negative control": "N.D.",
                "Description": "N.D."
            },
            "Validation controls P/LP": {
                "Validation controls P/LP": "N.D.",
                "Counts": "N.D."
            },
            "Validation controls B/LB": {
                "Validation controls B/LB": "N.D.",
                "Counts": "N.D."
            },
            "Statistical analysis method": {
                "Statistical analysis method": "N.D."
            },
            "Threshold for normal readout": {
                "Threshold for normal readout": "N.D.",
                "Source": "N.D."
            },
            "Threshold for abnormal readout": {
                "Threshold for abnormal readout": "N.D.",
                "Source": "N.D."
            },
            "Approved assay": {
                "Approved assay": "Yes"
            }
        },
        {
            "Assay Method": "TR-FRET kinase activity assays",
            "Material used": {
                "Material Source": "Protein",
                "Material Name": "LRRK2 (amino acids 970–2527) wild-type, G2019S, and I2020T",
                "Description": "N-terminal GST-tagged LRRK2 (amino acids 970–2527) wild-type, G2019S, and I2020T were from Invitrogen Corporation." 
            },
            "Readout type": "Quantitative",
            "Readout description": [
                {
                    "Variant": "NM_198578.3:c.6055G>A",
                    "Conclusion": "Abnormal",
                    "Molecular Effect": "N.D.",
                    "Result Description": "G2019S was modestly more sensitive to inhibition than wild-type LRRK2 with an IC50 value of 230 nM at 1mM ATP. At ATP Km,app, IC50 values for sunitinib were similar for all LRRK2 variants: 71, 74, and 75 µM for wild-type, G2019S, and I2020T, respectively." 
                },
                {
                    "Variant": "NM_198578.3:c.6059T>C",
                    "Conclusion": "Abnormal",
                    "Molecular Effect": "N.D.",
                    "Result Description": "I2020T was incompletely inhibited and had an IC50 value of at least 5 µM at 1mM ATP. At ATP Km,app, IC50 values for sunitinib were similar for all LRRK2 variants: 71, 74, and 75 µM for wild-type, G2019S, and I2020T, respectively." 
                }
            ],
            "Biological replicates": {
                "Biological replicates": "N.D.",
                "Description": "N.D."
            },
            "Technical replicates": {
                "Technical replicates": "Yes",
                "Description": "All assays were performed using either three or four replicates for each data point represented." 
            },
            "Basic positive control": {
                "Basic positive control": "Yes",
                "Description": "Reactions performed at 1 mM ATP included 24 nM wild-type, 8.3 nM G2019S, and 56 nM I2020T. Reactions performed with the ATP concentration equal to Km,app included 26 nM wild-type, 8.3 nM G2019S, and 53 nM I2020T." 
            },
            "Basic negative control": {
                "Basic negative control": "N.D.",
                "Description": "N.D."
            },
            "Validation controls P/LP": {
                "Validation controls P/LP": "N.D.",
                "Counts": "N.D."
            },
            "Validation controls B/LB": {
                "Validation controls B/LB": "N.D.",
                "Counts": "N.D."
            },
            "Statistical analysis method": {
                "Statistical analysis method": "N.D."
            },
            "Threshold for normal readout": {
                "Threshold for normal readout": "N.D.",
                "Source": "N.D."
            },
            "Threshold for abnormal readout": {
                "Threshold for abnormal readout": "N.D.",
                "Source": "N.D."
            },
            "Approved assay": {
                "Approved assay": "Yes"
            }
        }
    ]
}